Loading stock data…
$3.02-0.03 (-1.15%)
Check-Cap Ltd., a clinical stage medical diagnostics company, focuses on capsule-based screening technology products.
Check-Cap Ltd. in the Healthcare sector is trading at $3.01 with a market capitalization of $12M. Wall Street consensus targets $10.00 (1 analysts), implying a +232.2% move over the next 12 months. The stock is currently near its 52-week low of $3.00, remaining 69.1% below its 200-day moving average. On fundamentals, Piotroski 3/9 flags weak fundamentals, Altman Z in the distress zone. Risk note: RSI 25 is oversold, raising the odds of a near-term bounce. The Whystock Score of 55/100 suggests a balanced risk-reward profile.
| Metric (USD) | Q4 2025 | Q2 2025 | Q4 2024 | Q2 2024 |
|---|---|---|---|---|
| Total Revenue | — | — | — | — |
| Gross Profit | — | — | — | — |
| Operating Income | — | — | — | — |
| Net Income | — | — | — | — |
Check-Cap Ltd., a clinical stage medical diagnostics company, focuses on capsule-based screening technology products. Check-Cap Ltd. was incorporated in 2004 and is based in Isfiya, Israel.